Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized nilotinib study in spondyloarthritis
NL-OMON28855Active, not recruiting
- Sponsor
- AMC Health
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in spondyloarthritis (SpA) comparing Tasigna then open-label Tasigna with Placebo then open-label Tasigna (2 arms). Primary endpoints: Patient global assessment of disease activity, Physician global assessment of disease activity and 1 more. Started May 2011; status: active, not recruiting.
02
Drugs
nilotinib
03
Conditions
spondyloarthritis (SpA)
Beyond the preview
Go deeper on NL-OMON28855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28855.